- Home
- TILE vs PCRX Comparison
TILE vs PCRX Comparison
Compare TILE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- PCRX
- Stock Information
- Founded
- TILE 1973
- PCRX 2006
- Country
- TILE United States
- PCRX United States
- Employees
- TILE N/A
- PCRX N/A
- Industry
- TILE Home Furnishings
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- PCRX Health Care
- Exchange
- TILE Nasdaq
- PCRX Nasdaq
- Market Cap
- TILE 1.1B
- PCRX 1.1B
- IPO Year
- TILE N/A
- PCRX 2011
- Fundamental
- Price
- TILE $18.58
- PCRX $24.65
- Analyst Decision
- TILE Buy
- PCRX Buy
- Analyst Count
- TILE 1
- PCRX 9
- Target Price
- TILE $30.00
- PCRX $30.11
- AVG Volume (30 Days)
- TILE 611.2K
- PCRX 1.2M
- Earning Date
- TILE 05-02-2025
- PCRX 05-06-2025
- Dividend Yield
- TILE 0.22%
- PCRX N/A
- EPS Growth
- TILE 94.74
- PCRX N/A
- EPS
- TILE 1.48
- PCRX N/A
- Revenue
- TILE $1,315,658,000.00
- PCRX $700,966,000.00
- Revenue This Year
- TILE $4.21
- PCRX $9.48
- Revenue Next Year
- TILE $5.25
- PCRX $11.31
- P/E Ratio
- TILE $12.55
- PCRX N/A
- Revenue Growth
- TILE 4.29
- PCRX 3.85
- 52 Week Low
- TILE $14.13
- PCRX $11.16
- 52 Week High
- TILE $27.34
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- TILE 42.38
- PCRX 51.22
- Support Level
- TILE $17.96
- PCRX $24.10
- Resistance Level
- TILE $19.22
- PCRX $25.35
- Average True Range (ATR)
- TILE 1.01
- PCRX 1.49
- MACD
- TILE 0.01
- PCRX 0.01
- Stochastic Oscillator
- TILE 42.54
- PCRX 48.89
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.